CD19 and acute lymphoblastic leukemia: The high remission rates obtained with CD19‐CAR T cells in B‐ALL compare favorably to standard chemotherapy as well as to recently approved antibody‐based therapies, such as blinatumomab, a bispecific T cell engager (BiTE) directed against CD3 and CD19.